Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 1.00 |
| ▸ | CNR1 | P21554 | 12/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545961 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL1517462 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| SCHEMBL17414497 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL3746646 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL1649687 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL1517460 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL5449597 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| SCHEMBL17414495 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL6954142 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 | |
| Dexanabinol SCHEMBL31545009 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180354876-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | E-THERAPEUTICS PLC (GB) | 2018-12-13 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354876-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | CNR1, CNR2, OPRK1 | CNR2 2/4885CNR1 1/4885GLRA1 140/4885 |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | CNR2 1/4885CNR1 2/4885GLRA1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.